Clinical Trials | October 01, 2025
Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The new site enables end-to-end production of viral vector gene therapies
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Cagrilintide represents a novel approach to obesity management
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Subscribe To Our Newsletter & Stay Updated
